{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/DLB/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-10T06:02:18.820Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":2690,"canonical_name":"Dolby Laboratories, Inc.","cik":"0001308547","uei":null,"lei":null,"duns":null,"ticker":"DLB"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":25},"count":25,"timeline":[{"ts":"2026-09-11","kind":"sec.filing","form_type":"S-8","title":"S-8 — Dolby Laboratories, Inc. — 2026-09-11","url_slug":"/sec/cik-0001308547/s-8/0001193125-26-389337","accession_number":"0001193125-26-389337","importance":30},{"ts":"2026-07-06","kind":"sec.filing","form_type":"4","title":"4 — Dolby Laboratories, Inc. — 2026-07-06","url_slug":"/sec/cik-0001308547/4/0001193125-26-296456","accession_number":"0001193125-26-296456","importance":30},{"ts":"2026-07-01","kind":"sec.form144","reporter":"JOHN COULING","title":"Officer","shares":7667,"usd_value":407894,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001950047-26-006710","importance":40.081578874},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Couling John D","title":"SVP, Entertainment","shares":7667,"price_per_share":53.2013,"usd_value":407894,"security_title":"Class A Common Stock","importance":35.4078943671},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Dolby Laboratories, Inc. — 2026-07-01","url_slug":"/sec/cik-0001308547/144/0001950047-26-006710","accession_number":"0001950047-26-006710","importance":30},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Couling John D","title":"SVP, Entertainment","shares":7667,"price_per_share":45.5,"usd_value":348849,"security_title":"Class A Common Stock","importance":15.3488485},{"ts":"2026-06-04","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Dolby Laboratories, Inc. — 2026-06-04","url_slug":"/sec/cik-0001308547/schedule-13g-a/0002012383-26-001861","accession_number":"0002012383-26-001861","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Dolby Laboratories, Inc. — 2026-06-03","url_slug":"/sec/cik-0001308547/4/0001193125-26-255624","accession_number":"0001193125-26-255624","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"JOHN COULING","title":"Officer","shares":7666,"usd_value":426420,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001950047-26-005351","importance":40.085283944},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Couling John D","title":"SVP, Entertainment","shares":7158,"price_per_share":55.5868,"usd_value":397890,"security_title":"Class A Common Stock","importance":35.3978903144},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Couling John D","title":"SVP, Entertainment","shares":508,"price_per_share":56.16,"usd_value":28529,"security_title":"Class A Common Stock","importance":35.02852928},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — Dolby Laboratories, Inc. — 2026-06-01","url_slug":"/sec/cik-0001308547/144/0001950047-26-005351","accession_number":"0001950047-26-005351","importance":30},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Couling John D","title":"SVP, Entertainment","shares":7666,"price_per_share":45.5,"usd_value":348803,"security_title":"Class A Common Stock","importance":15.348803},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — Dolby Laboratories, Inc. — 2026-05-19","url_slug":"/sec/cik-0001308547/4/0001193125-26-231170","accession_number":"0001193125-26-231170","importance":30},{"ts":"2026-05-18","kind":"sec.insider.f","reporter":"Revankar Shriram","title":"SVP, Advanced Technology Group","shares":4329,"price_per_share":54.21,"usd_value":234675,"security_title":"Class A Common Stock","importance":15.23467509},{"ts":"2026-05-15","kind":"sec.form144","reporter":"SHRIRAM REVANKAR","title":"Officer","shares":3000,"usd_value":164700,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001950047-26-004571","importance":40.03294},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Revankar Shriram","title":"SVP, Advanced Technology Group","shares":3000,"price_per_share":54.9,"usd_value":164700,"security_title":"Class A Common Stock","importance":35.1647},{"ts":"2026-05-15","kind":"sec.filing","form_type":"144","title":"144 — Dolby Laboratories, Inc. — 2026-05-15","url_slug":"/sec/cik-0001308547/144/0001950047-26-004571","accession_number":"0001950047-26-004571","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Dolby Laboratories, Inc. — 2026-05-14","url_slug":"/sec/cik-0001308547/4/0001193125-26-224607","accession_number":"0001193125-26-224607","importance":30},{"ts":"2026-05-12","kind":"sec.form144","reporter":"ROBERT PARK","title":"Officer","shares":4895,"usd_value":277425,"security_title":"Common","approx_sale_date":"2026-05-12","accession_number":"0001950047-26-004379","importance":40.055484922},{"ts":"2026-05-12","kind":"sec.insider.s","reporter":"Park Robert J","title":"SVP & Chief Financial Officer","shares":4504,"price_per_share":56.6165,"usd_value":255001,"security_title":"Class A Common Stock","importance":35.255000716},{"ts":"2026-05-12","kind":"sec.insider.s","reporter":"Park Robert J","title":"SVP & Chief Financial Officer","shares":391,"price_per_share":57.35,"usd_value":22424,"security_title":"Class A Common Stock","importance":35.02242385},{"ts":"2026-05-12","kind":"sec.filing","form_type":"144","title":"144 — Dolby Laboratories, Inc. — 2026-05-12","url_slug":"/sec/cik-0001308547/144/0001950047-26-004379","accession_number":"0001950047-26-004379","importance":30},{"ts":"2026-05-11","kind":"sec.13dg","reporter":"Dolby Laboratories, Inc.","shares":5020777,"percent_of_class":8.2,"security_title":"SCHEDULE 13G/A","accession_number":"0000895421-26-000141","excerpt":null,"importance":55},{"ts":"2026-05-11","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Dolby Laboratories, Inc. — 2026-05-11","url_slug":"/sec/cik-0001308547/schedule-13g-a/0000895421-26-000141","accession_number":"0000895421-26-000141","importance":30}]}